INNOVATING PATIENT-FIRST CANCER TREATMENT

ASTRO 2019

September 15-18
McCormick Place West
Chicago, IL

CLINICAL HIGHLIGHTS FROM ASTRO 2019

Clinicians and researchers presented several clinical studies at ASTRO 2019, adding to the large body of real-world proof of the clinical effectiveness and safety of Accuray innovations in the treatment of a range of diseases:

HDR-Like Prostate SBRT with CyberKnife

HDR-Like Prostate Stereotactic Body Radiotherapy: Evaluation of PSA kinetics, Clinical Relapse-free Survival and Adverse Events Beyond 5 years in a Multi-institutional Study

A prospective, multi-center study of men diagnosed with low- or intermediate-risk prostate cancer found that at 7 years post CyberKnife treatment, the biochemical relapse-free survival is 91.1% (100% for low risk and 84.7% for intermediate risk). These results are consistent with the 5-year outcomes previously reported.

Whole Brain Irradiation with TomoTherapy

Phase II Clinical Trial of Hippocampal-Sparing Whole Brain Irradiation and Simultaneous Integrated Boost Tomotherapy (SIB-TOMO) for Brain Metastases in Patients with Lung Cancer

A phase II study indicates that the TomoTherapy System provides a feasible option for the treatment of brain metastases resulting from lung cancer. Patients were treated with hippocampal-sparing whole brain irradiation and simultaneous integrated boost with TomoTherapy, which provided a better local control rate for the metastatic lesions, reduced the probability of recurrence and protected neurocognitive function.

Comparison of VMAT and Helical RT in Breast Cancer Treatment

Dosimetric Comparison of Simultaneous-Integrated BOOST and Sequential BOOST with VMAT or Helical Tomotherapy in Breast Cancer Patients after Breast-Conserving Surgery

A planning study evaluated the feasibility of using volumetric-arc radiotherapy (VMAT) and helical TomoTherapy (HT) to deliver simultaneous-integrated-boost (SIB) irradiation to breast tumors. Results suggest that for irradiation after breast conserving surgery, HT provides several advantages.

Robotic SBRT Optimization

Performance Assessment of a New Optimization System for Robotic SBRT Plans

Clinicians compared treatment plans generated with the CyberKnife VOLO Optimizer and Sequential Optimizer for 25 cases including liver, prostate, pancreas, and spinal. Use of the VOLO Optimizer resulted in higher plan quality while reducing average estimated treatment delivery time, and significantly reducing optimization time, for all cases.

Long-Term Outcomes of Prostate SBRT

Long-Term Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer

A multi-center study of men with low- or intermediate-risk cancer found that disease free survival rates 8 years after treatment with CyberKnife remain favorable for both low- and intermediate-risk groups (98.7% for intermediate risk and 93.7% for high-risk).

Prostate SBRT with Intraprostatic Dose Escalation

5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer

Clinicians investigating the use of the CyberKnife System for the treatment of unfavorable intermediate- or high-risk prostate cancer reported excellent outcomes. For men who received the higher dose, the 5-year biochemical relapse-free survival was 91.9%, and for those receiving the lower dose, it was 85.1%.

UNVEILED AT ASTRO 2019: SYNCHRONY® FOR RADIXACT®

Accuray brings our revolutionary and industry-exclusive motion synchronization technology from the CyberKnife® System to the Radixact® Treatment Delivery System. See how Radixact motion synchronization completely redefines the standards for delivering powerfully precise, safe and highly efficient treatments to any target — even those moving with respiration.

radixact_icon_art
experttheater

MORE INDUSTRY EXPERTISE FROM ASTRO 2019

ACCURAY SYMPOSIUM

Dynamic Tracking and Motion Synchronization: Over 15 Years of Accuray Leadership

Monday, September 16 – 12:15pm-1:15pm

  • Chairman & Introduction: Iris C. Gibbs, M.D., FACR, FASTRO, Stanford University Medical Center, Stanford (CA)
  • Clinical Value of Motion Synchronization for Prostate SBRT: Ronald C. Chen, M.D. M.P.H., University of North Carolina, Chapel Hill (NC)
  • Clinical Value of Motion Synchronization for Lung SBRT: Jonathan W. Lischalk, M.D., JMedstar Georgetown University Hospital, Washington (DC)
  • First Site Experience with Real-time Motion Synchronization on the Radixact System: Allen Li, Ph.D., DABMP, FAAPM, Medical College of Wisconsin, Milwaukee (WI)

AERO ACADEMY PROGRAM

20-minute talks on real-world experiences and proven best practices—right in the Accuray booth, no reservation required. This year’s topics include:
  • Synchrony Motion Synchronization for the Radixact System
  • The CyberKnife VOLO™ Experience
  • CyberKnife for Prostate SBRT, Liver and Brain Metastases
  • TomoTherapy® for Breast and Advanced Rectal Cancers
  • Medicare Radiation Oncology Alternative Payment Model, What it Means to Your Practice
  • And more!

Important Safety Information
Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury, and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), and the patient’s general medical condition, to name a few. For more details about the side effects of your radiation therapy, and to see if treatment with an Accuray product is right for you, ask your doctor.

Start typing and press Enter to search